Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions
Therapeutic Allogeneic Lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Germ Cell Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
keyhole limpet hemocyanin, tetanus toxoid
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian Function Following Intraovarian Injection of PRP

NCT04278313
Conditions
Diminished Ovarian Reserve, Diminished Ovarian Reserve Due to Advanced Maternal Age
Interventions
PRP - Platelet Rich Plasma, PPP - Platelet Poor Plasma
Procedure
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 44 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
dolutegravir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Multiple Myeloma
Interventions
Velcade, Cyclophosphamide, Revlimid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Biopsy Specimen Radiography, Lenalidomide, Vaccine Therapy
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Isatuximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Conditions
Multiple Myeloma, Plasma Cell Disorder
Interventions
HDP-101
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
39
States / cities
Little Rock, Arkansas • Berkeley, California • Duarte, California + 31 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Blood Donation Study for ALPCO Syphilis-T and Syphilis-NT Assay Development

NCT07830550
Conditions
Healthy Volunteers, Syphilis Serologic Assay Development, Blood Specimen Collection, Diagnostic Assay Development, Serum Specimen Collection
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salem, New Hampshire
Conditions
Multiple Myeloma
Interventions
LGH447, midazolam
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Conditions
Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
melphalan, amifostine trihydrate, peripheral blood stem cell transplantation, fluorescence in situ hybridization, bone marrow ablation with stem cell support
Drug · Procedure · Genetic
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
4
States / cities
Los Angeles, California • Rochester, New York • Seattle, Washington
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
Interventions
MLN9708
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Multiple Myeloma
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Miami Shores, Florida • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Lafayette, Indiana • Omaha, Nebraska + 1 more
Conditions
Multiple Myeloma
Interventions
Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Beech Grove, Indiana • New York, New York • Winston-Salem, North Carolina + 6 more
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
SOM230, Bortezomib, Dexamethasone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Multiple Myeloma
Interventions
Bendamustine, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Suzanne Lentzsch, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL)
Interventions
APG-3288
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 2 more
Completed No phase listed Observational

B-Receptor Signaling in Cardiomyopathy

NCT01135849
Conditions
Carcinomas, Amyloidosis, Anal Cancer, Anemia, Cholangiocarcinoma of the Extrahepatic Bile Duct, Transitional Cell Carcinoma of Bladder, Bone Marrow Transplant Failure, Bone Cancer, Cancer of Brain and Nervous System, Breast Cancer, Carcinoma of the Large Intestine, Endocrine Cancer, Esophageal Cancer, Eye Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Gynecologic Cancers, Head and Neck Cancers, Hepatobiliary Neoplasm, Kidney (Renal Cell) Cancer, Leukemia, Lung Cancer, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Neuroendocrine Tumors, Myeloproliferative Disorders, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Daniel Bernstein
Other
Eligibility
Up to 40 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California